IMC Chicago’s Caris Life Sciences CAI Stock Holding History

IMC Chicago’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$412K	Buy	23,148 +10,229	+79%	+$183K	﹤0.01%	4868
2026 Q1	$231K	Buy	+12,919	New	+$282K	﹤0.01%	4850

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

SSP

Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

IMC Chicago's CAI Position: Q2 2026 in Review

IMC Chicago increased its Caris Life Sciences (CAI) stake by 79% in Q2 2026, buying an estimated $183K and bringing the position to 23,148 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #4868.

IMC Chicago first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

IMC Chicago held 23,148 shares of Caris Life Sciences worth $412K as of Q2 2026.
IMC Chicago bought 10,229 Caris Life Sciences shares in Q2 2026, an estimated $183K.
Caris Life Sciences made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4868 holding.
IMC Chicago first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.